Pharmacological challenge reveals long-term effects of perinatal phencyclidine on delayed spatial alternation in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 5, 2003, Pages 867-873

  Wiley, Jenny L ^a   Bühler, Katriona G ^a   Lavecchia, Kari L ^a   Johnson, Kenneth M ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Amphetamine; Dizocilpine; Glutamate; Phencyclidine; Schizophrenia

Indexed keywords

AMPHETAMINE; DIZOCILPINE; DOPAMINE RECEPTOR STIMULATING AGENT; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

ACCURACY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; COGNITION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; INJECTION; NEUROTOXICITY; NEWBORN; NONHUMAN; PREFRONTAL CORTEX; PROVOCATION TEST; RAT; RECEPTOR AFFINITY; STATISTICAL SIGNIFICANCE; TASK PERFORMANCE;

EID: 0042632840     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00146-5     Document Type: Article

References (46)

1. Aceto M.D., Martin B.R., Uwaydah I.M., May E.L., Harris L.S., Izazola-Conde C., Dewey W.L., Vincek W.C. Optically pure (+)-nicotine from (±)-nicotine and biological comparisons with (-)-nicotine. J. Med. Chem. 22:1979;174-177.
2. Andreasen N.C. Linking mind and brain in the study of mental illnesses: a project for a scientific psychopathology. Science. 275:1997;1586-1593.
3. Baron S.P., Moerschbaecher J.M. Disruption of learning by excitatory amino acid receptor antagonists. Behav. Pharmacol. 6:1996;573-584.
4. Baron S.P., Wright D., Wenger G.R. Effects of drugs of abuse and scopolamine on memory in rats: delayed spatial alternation and matching to position. Psychopharmacology. 137:1998;7-14.
5. Braff D.L., Stone C., Callaway E., Geyer M.A., Glick I.D., Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology. 15:1978;339-343.
6. Brooks W.J., Weeks A.C.W., Leboutillier J.C., Petit T.L. Altered NMDA sensitivity and learning following chronic developmental NMDA antagonism. Physiol. Behav. 62:1997;955-962.
7. Bushnell P.J., Levin E.D. Effects of dopaminergic drugs on working and reference memory in rats. Pharmacol. Biochem. Behav. 45:1993;765-776.
8. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186.
9. Carter C.S., Freeman J.H. Jr., Stanton M.E. Neonatal medial prefrontal lesions and recovery of spatial delayed alternation in the rat: effects of delay interval. Dev. Psychobiol. 28:1995;269-279.
10. Crespo-Facorro B., Wiser A.K., Andreasen N.C., O'Leary D.S., Watkins G.L., Boles Ponto L.L., Hichwa R.D. Neural basis of novel and well-learned recognition memory in schizophrenia: a positron emission tomography study. Hum. Brain Mapp. 12:2001;219-231.
11. Doyle K., Feerick S., Kirkby D.L., Eddleston A., Higgins G.A. Comparison of various N-methyl-D-aspartate receptor antagonists in a model of short-term memory and on overt behaviour. Behav. Pharmacol. 9:1998;671-681.
12. Feeser H.R., Raskin L.A. Effects of neonatal dopamine depletion on spatial ability during ontogeny. Behav. Neurosci. 101:1987;812-818.
13. France C.P., Moerschbaecher J.M., Woods J.H. MK-801 and related compounds in monkeys: discriminative stimulus effects and effects on a conditional discrimination. J. Pharmacol. Exp. Ther. 257:1991;727-734.
14. Freeman J.H. Jr., Stanton M.E. Medial prefrontal cortex lesions and spatial delayed alternation in the developing rat: recovery or sparing? Behav. Neurosci. 106:1992;924-932.
15. Goldman-Rakic P.S., Selemon L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr. Bull. 23:1997;437-458.
16. Gorter J.A., Botterblom M.H.A., Feenstra M.G.P., Boer G.J. Chronic neonatal NMDA receptor blockade with MK-801 alters monoamine metabolism in the adult rat. Neurosci. Lett. 137:1992;97-100.
17. Green R.J., Stanton M.E. Differential ontogeny of working memory and reference memory in the rat. Behav. Neurosci. 103:1989;98-105.
18. Harrison P.J., McLaughlin D., Kerwin R.W. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet. 337:1991;450-452.
19. Hertel P., Mathe J.M., Nomikos G.G., Iurlo M., Mathe A.A., Svensson T.H. Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav. Brain Res. 72:1996;103-114.
20. Hughes J.R., Hatsukami D.K., Mitchell J.E., Dahlgren L.A. Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry. 143:1986;993-997.
21. Ikonomidou C., Bosch F., Miksa M., Bittigau P., Vockler J., Dikranian K., Tenkova T.I., Stefovsak V., Turski L., Olney J.W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 283:1999;70-74.
22. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
23. Kesner R.P., Bierley R.A., Pebbles P. Short-term memory: the role of d-amphetamine. Pharmacol. Biochem. Behav. 15:1981;673-676.
24. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch. Gen. Psychiatry. 51:1994;199-214.
25. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
26. Levin E.D. Nicotinic receptor subtypes and cognitive function. J. Neurobiol. 53:2002;633-640.
27. Macciardi F., Lucca A., Catalano M., Marino C., Zanardi R., Smeraldi E. Amino acid patterns in schizophrenia: some new findings. Psychiatry Res. 32:1990;63-70.
28. Mansbach R.S., Geyer M.A. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology. 2:1989;299-308.
29. Maren S., Baudry M., Thompson R.F. Differential effects of ketamine and MK-801 on the induction of long-term potentiation. NeuroReport. 2:1991;239-242.
30. Marenco S., Weinberger D.R. The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev. Psychopathol. 12:2000;501-527.
31. Mirza N.R., Stolerman I.P. Nicotine enhances sustained attention in the rat under specific task conditions. Psychopharmacology. 138:1998;266-274.
32. Moghaddam B. Recent basic findings in support of excitatory amino acid hypotheses of schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 18:1994;859-870.
33. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17:1997;2921-2927.
34. National Research Council Guide for the Care and Use of Laboratory Animals. 1996;National Academy Press, Washington, DC.
35. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 244:1989;1360-1362.
36. Puma C., Deschaux O., Molimard R., Bizot J.C. Nicotine improves memory in an object recognition task in rats. Eur. Neuropsychopharmacol. 9:1999;323-327.
37. Rezvani A.H., Bushnell P.J., Levin E.D. Effects of nicotine and mecamylamine on choice accuracy in an operant visual signal detection task in female rats. Psychopharmacology. 164:2002;369-375.
38. Sircar R., Veliskova J., Moshe S.L. Chronic neonatal phencyclidine treatment produces age-related changes in pentylenetetrazol-induced seizures. Dev. Brain Res. 81:1994;185-191.
39. Smith D.H., Okiyama K., Thomas M.J., Claussen B., McIntosh T.K. Evaluation of memory dysfunction following experimental brain injury using the Morris water maze. J. Neurotrauma. 8:1991;259-269.
40. Socci D.J., Sanberg P.R., Arendash G.W. Nicotine enhances Morris water maze performance of young and aged rats. Neurobiol. Aging. 16:1995;857-860.
41. Stanhope K.J., McLenachan A.P., Dourish C.T. Dissociation between cognitive and motor/motivational deficits in the delayed matching to position test: effects of scopolamine, 8-OH-DPAT and EAA antagonists. Psychopharmacology. 122:1995;268-280.
42. Verma A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16:1996;373-379.
43. Wang C., McInnis J., Ross-Sanchez M., Shinnick-Gallagher P., Wiley J.L., Johnson K.M. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience. 107:2001;535-550.
44. Watkins J.C. The NMDA receptor concept: origins and development. Watkins J.C., Collingridge G.L. The NMDA Receptor. 1989;1-17 Oxford Univ. Press, Oxford.
45. Willmore C.B., Bespalov A.Y., Beardsley P.M. Competitive and noncompetitive NMDA antagonist effects in rats trained to discriminate lever-press counts. Pharmacol. Biochem. Behav. 69:2001;493-502.
46. Willmore C.B., LaVecchia K.L., Wiley J.L. NMDA antagonists produce site-selective impairment of accuracy in a delayed nonmatch-to-sample task in rats. Neuropharmacology. 41:2001;916-927.